WallStSmart

Amphenol Corporation (APH)vsIQVIA Holdings Inc (IQV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amphenol Corporation generates 56% more annual revenue ($25.90B vs $16.63B). APH leads profitability with a 17.2% profit margin vs 8.3%. IQV appears more attractively valued with a PEG of 0.72. APH earns a higher WallStSmart Score of 74/100 (B).

APH

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 9.0Value: 6.7Quality: 6.8
Piotroski: 4/9Altman Z: 2.36

IQV

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 8.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APHUndervalued (+53.3%)

Margin of Safety

+53.3%

Fair Value

$312.78

Current Price

$122.47

$190.31 discount

UndervaluedFair: $312.78Overvalued
IQVUndervalued (+31.6%)

Margin of Safety

+31.6%

Fair Value

$259.19

Current Price

$173.55

$85.64 discount

UndervaluedFair: $259.19Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APH5 strengths · Avg: 9.0/10
Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

Revenue GrowthGrowth
58.4%10/10

Revenue surging 58.4% year-over-year

Market CapQuality
$168.07B9/10

Large-cap with strong market position

Operating MarginProfitability
27.3%8/10

Strong operational efficiency at 27.3%

EPS GrowthGrowth
24.1%8/10

Earnings expanding 24.1% YoY

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

PEG RatioValuation
0.728/10

Growing faster than its price suggests

Areas to Watch

APH2 concerns · Avg: 4.0/10
P/E RatioValuation
39.3x4/10

Premium valuation, high expectations priced in

Price/BookValuation
10.8x4/10

Trading at 10.8x book value

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : APH

The strongest argument for APH centers on Return on Equity, Revenue Growth, Market Cap. Profitability is solid with margins at 17.2% and operating margin at 27.3%. Revenue growth of 58.4% demonstrates continued momentum.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.

Bear Case : APH

The primary concerns for APH are P/E Ratio, Price/Book.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Key Dynamics to Monitor

APH profiles as a growth stock while IQV is a value play — different risk/reward profiles.

APH carries more volatility with a beta of 1.30 — expect wider price swings.

APH is growing revenue faster at 58.4% — sustainability is the question.

APH generates stronger free cash flow (830M), providing more financial flexibility.

Bottom Line

APH scores higher overall (74/100 vs 66/100), backed by strong 17.2% margins and 58.4% revenue growth. IQV offers better value entry with a 31.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphenol Corporation

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Amphenol Corporation is a major producer of electronic and fiber optic connectors, cable and interconnect systems such as coaxial cables. Amphenol is a portmanteau from the corporation's original name, American Phenolic Corp.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?